Building Clinical Trials Capacity for Tuberculosis Drugs in High-Burden Countries
(2007; 4 pages)


The standard preferred regimen for the treatment of drug-susceptible tuberculosis (TB) around the world consists of a two-month induction phase of isoniazid, rifampin, pyrazinamide, and ethambutol followed by a continuation phase of four months of isoniazid and rifampin. This regimen has several advantages:

  1. it is essentially completely effective in achieving sputum culture conversion;
  2. it is relatively inexpensive and universally available;
  3. the relapse rate is low, at 3%–5%; and
  4. it can be administered largely intermittently. But the regimen has significant limitations.

These limitations can only be overcome by building TB clinical trials capacity.

El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019